SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as investors discuss the potential impact of upcoming 48-week data and a recent FDA policy change that could expedite drug approvals. Community members are debating the significance of statistical improvements and speculating on potential buyout scenarios, comparing ALT's potential to competitors in the MASH and weight loss space. Bullish sentiment revolves around best-in-class potential, while bears cite concerns about trial results and dilution.

Cemtrex, Inc. engages in the provision of solutions in the technology industry. It operates through the following segments: Security, Industrial Services, and Cemtrex Corporate. The Security segment provides end-to-end security solutions to meet corporate, industrial, and governmental security challenges. The Industrial Services segment offers single-source expertise and services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly to diversified customers. The Cemtrex Corporate segment refers to the holding company of the other two segments. The company was founded on April 27, 1998 and is headquartered in Hauppauge, NY.

Cemtrex Inc.

Cemtrex ($CETX) is experiencing significant volatility and high volume, drawing comparisons to recent high-flying nano-cap stocks like $SMX and $TWG, leading to speculation about a potential short squeeze. The community is closely watching price action, particularly around key levels like $8 and $9, with many anticipating a surge in after-hours trading. Discussions also include the potential for extreme price targets and the impact of high borrow rates on short positions.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

TWG is trending due to a potential short squeeze, with community members actively discussing its low float and comparing it to previous high-flying stocks like $CETX and $TGL. The stock's significant price movement and multiple trading halts have fueled speculation about further gains, particularly in after-hours trading, where halts are not in effect. Some traders are also pointing to the company's improved financials as a reason for the stock's recent surge.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Recent news of a potential acquisition deal with Warner Bros. Discovery (WBD) has sparked volatility in Netflix (NFLX) stock, leading to active discussions among investors. Community members are weighing the pros and cons of the deal, including potential regulatory hurdles, debt implications, and the emergence of competing bids from companies like Paramount. Broader sector restructuring and potential impacts on ad revenue and market competition are also being closely monitored.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana's addition to the S&P 500 is fueling bullish momentum, while some traders question the company's valuation and fundamentals amidst an ongoing SEC investigation. Community members are actively debating whether the surge is sustainable or a sign of an overextended market, pointing to the stock's dramatic rise from near bankruptcy. Discussions also include the potential impact on index funds and the broader used car market.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences ($WVE) is trending after positive early data for its obesity drug, WVE-007, showing promising fat loss and muscle gain. The community is buzzing about the potential for this drug to rival existing treatments and is actively discussing potential offerings. Some traders are also eyeing shorting opportunities while others see potential for a larger squeeze.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals (TERN) is trending following positive Phase 1 data for its leukemia drug TERN-701, with community members discussing its potential to disrupt the CML treatment landscape and challenge existing market leaders. Analysts have upgraded TERN, citing the drug's efficacy and safety profile, leading to increased investor confidence and a potential buy-out. Some traders are wary of a possible offering given the increase.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is trending as investors discuss its recent pullback and potential for a rebound, focusing on the company's strong growth prospects and the upcoming integration of Alani Nu into PepsiCo's distribution network. Community members are debating whether the current price represents a buying opportunity, citing both technical indicators and the company's fundamentals. Discussions also involve speculation about potential buybacks and future price targets, with some expressing concerns about insider selling.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

GPCR is trending due to positive topline data from its ACCESS program, highlighting the potential of its oral GLP-1 aleniglipron in weight loss. Community discussions revolve around the drug's efficacy and safety profile compared to competitors, with some speculating on potential acquisition bids. The stock is seen as a strong momentum play with a low-float biotech profile, making it attractive to investors.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance (PSKY) is trending amid news of a hostile all-cash bid for Warner Bros. Discovery (WBD), challenging Netflix's (NFLX) acquisition plans. Community discussions revolve around the offer's structure, regulatory hurdles, and potential impact on competition in the streaming landscape, with some highlighting potential political factors influencing the deal. The battle for WBD is seen as a pivotal moment for the future of streaming and media consolidation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

StockTwits for iOS

Harmony Biosciences Holdings Inc

Broview

@Broview 28% forward earnings that&#39;s good growth, could be a short squeeze, 8% short interest and 5 days to unwind it.

StockTwits Web

 28% forward earnings that's good growth, could be a short squeeze, 8% short interest and 5 days to unwind it.